((自动化翻译由路透提供，请见免责声明 ))
10月22日 - ** CorvusPharmaceuticals 股价在盘前交易中上涨6.5%至8.05美元
** 瑞穗将股票评级从 "中性 "上调至 "跑赢大盘"；目标价从3.5美元上调至12美元
** 券商看好 CRVS 实验性药物 soquelitinib 的新势头
** CRVS正在测试将soquelitinib作为治疗罕见白细胞癌和特应性皮炎或湿疹的药物。
** 经纪公司上调了对该药的预期，原因是美国上市年的价格假设提高了，而且湿疹药物带来了新的收入贡献等。
** 美国约有 200 万患者对一线治疗产生耐药性 ，湿疹代表着巨大的市场机遇--券商
** 补充说，CRVS 认为该药物在多达 14 种其他免疫疾病中也有潜在用途
** 预计不久将获得特应性皮炎的早期数据 ，券商称积极的数据 将提供关键的验证，并使 CVRS 的股价大幅上涨
** 覆盖该股的分析师的平均评级为 "买入"；中位数为 8 美元--LSEG 数据
** 截至上一交易日收盘，该股股价在过去一年中上涨了四倍多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.